The estimated Net Worth of Wendall Wierenga is at least $1.46 Million dollars as of 27 December 2023. Wendall Wierenga owns over 10,000 units of Crinetics Pharmaceuticals Inc stock worth over $1,200,153 and over the last 21 years he sold CRNX stock worth over $0. In addition, he makes $264,250 as Independent Chairman of the Board at Crinetics Pharmaceuticals Inc.
Wendall has made over 8 trades of the Crinetics Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of CRNX stock worth $44,400 on 27 December 2023.
The largest trade he's ever made was exercising 25,329 units of Crinetics Pharmaceuticals Inc stock on 28 April 2020 worth over $18,490. On average, Wendall trades about 1,054 units every 46 days since 2003. As of 27 December 2023 he still owns at least 23,653 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Wendall Wierenga stock trades at the bottom of the page.
Dr. Wendall Wierenga Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Wierenga brings to our board over four decades of experience in research, drug discovery and drug development, including clinical research, regulatory affairs, manufacturing, safety, and medical affairs. He has an extensive background serving as a public company executive and board member in the pharmaceutical and biotechnology industries. He most recently served as Executive Vice President, Research and Development, at Santarus, Inc., a specialty biopharmaceutical company, from June 2011 until its acquisition by Salix Pharmaceuticals, Inc. in 2014. Prior to Santarus, he was Executive Vice President of Research and Development at Ambit Biosciences Corporation from 2007 until 2011 and Neurocrine Biosciences, Inc. from 2003 until 2006. Additionally, Dr. Wierenga served as Chief Executive Officer of Syrrx, Inc. (now part of Takeda Pharmaceutical Company), Senior Vice President of Worldwide Pharmaceutical Sciences, Technologies and Development at Parke-Davis/Warner Lambert Company LLC (now Pfizer, Inc.), and he spent 16 years at Upjohn Pharmaceuticals in research and drug discovery roles. Dr. Wierenga serves as a member of the board of directors of Dermata Therapeutics, LLC, a private company. He also serves on the board of Cytokinetics Inc., a publicly-traded biopharmaceutical company. He was previously on the board of directors of Onyx Pharmaceuticals, Inc. (acquired by Amgen), Anacor Pharmaceuticals Inc. (acquired by Pfizer) XenoPort, Inc. (acquired by Arbor Pharmaceuticals), Ocera Therapeutics Inc. (acquired by Mallinckrodt), Apricus Biosciences, Inc. (acquired by Seelos), Patara Pharma LLC (acquired by Respivant), and Concert Pharmaceuticals, Inc. Additionally, Dr. Wierenga serves on several scientific advisory boards, including Sojournix, Inc., Ferring Pharmaceuticals, and Ocelot Bio. He holds a Ph.D. in Chemistry from Stanford University and a B.A. in Chemistry from Hope College. Dr. Wierenga’s scientific.
As the Independent Chairman of the Board of Crinetics Pharmaceuticals Inc, the total compensation of Wendall Wierenga at Crinetics Pharmaceuticals Inc is $264,250. There are 7 executives at Crinetics Pharmaceuticals Inc getting paid more, with R. Scott Struthers having the highest compensation of $3,766,660.
Wendall Wierenga is 72, he's been the Independent Chairman of the Board of Crinetics Pharmaceuticals Inc since 2015. There are no older and 18 younger executives at Crinetics Pharmaceuticals Inc.
Wendall's mailing address filed with the SEC is 350, Oyster Point Boulevard, South San Francisco, San Mateo County, California, 94080, United States.
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over $52,514,606 worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth $62,800,483 . The most active insiders traders include Advisors Llcperceptive Life..., Jack Nielsen, and Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $3,116,248. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth $159,570.
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include: